1

1	
2	Neuron loss in the brain starts in childhood, increases exponentially with age and is halted by GM-CSF
3	treatment in Alzheimer's disease
4 5	
6	Stefan H. Sillau, ^{1†} Christina Coughlan, ^{1,2†} Md. Mahiuddin Ahmed, ^{1,2†} Kavita Nair, ^{1,3} Paula Araya, ² Matthew
7	D. Galbraith, ^{2,4} Brianne M. Bettcher, ^{1,2} Joaquin M. Espinosa, ^{2,4} Heidi J. Chial, ^{1,2} Neill Epperson, ⁵ Timothy
8	D. Boyd, ^{1,2} Huntington Potter ^{1,2*}
9	
10	1. Department of Neurology and the University of Colorado Alzheimer's and Cognition Center, University
11	of Colorado Anschutz Medical Campus, Aurora, CO
12	2. Linda Crnic Institute for Down Syndrome, University of Colorado, Anschutz Medical Campus, Aurora,
13	CO
14	3. Department of Clinical Pharmacy, Center for Pharmaceutical Outcomes Research (CePOR)
15	4. Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO
16	5. Department of Psychiatry, University of Colorado Anschutz Medical Campus, Aurora, CO
17	
18	[†] These authors contributed equally to this work: S. H. Sillau, C. Coughlan, and Md. M. Ahmed
19	*Corresponding author: H. Potter (Huntington.Potter@cuanschutz.edu)
20	
21	
22	
23	
24	

25 Summary

26 Aging increases the risk of neurodegeneration, cognitive decline, and Alzheimer's disease (AD). Currently 27 no means exist to measure neuronal cell death during life or to prevent it. Here we show that cross-sectional 28 measures of human plasma proteins released from dying/damaged neurons (ubiquitin C-terminal hydrolase-29 L1/UCH-L1 and neurofilament light/NfL) become exponentially higher from age 2-85; UCH-L1 rises faster 30 in females. Glial fibrillary acidic protein (GFAP) concentrations, indicating astrogliosis/inflammation, 31 increase exponentially after age 40. Treatment with human granulocyte-macrophage colony-stimulating 32 factor (GM-CSF/sargramostim) halted neuronal cell death, as evidenced by reduced plasma UCH-L1 33 concentrations, in AD participants to levels equivalent to those of five-year-old healthy controls. The ability 34 of GM-CSF treatment to reduce neuronal apoptosis was confirmed in a rat model of AD. These findings 35 suggest that the exponential increase in neurodegeneration with age, accelerated by neuroinflammation, may 36 underlie the contribution of aging to cognitive decline and AD and can be halted by GM-CSF/sargramostim 37 treatment.

38

Key words: Aging, Neurodegeneration, Alzheimer, granulocyte-macrophage colony stimulating factor,
ubiquitin C-terminal hydrolase-L1, neurofilament light, glial fibrillary acidic protein, senolysis,
neuroprotection

42

43

44 Acknowledgements

- 45 National Institutes of Health grant R01AG071151 (HP)
- 46 National Institutes of Health grant R01AI50305, (JE)
- 47 The State of Colorado (HP)
- 48 Alzheimer's Association Part the Cloud grant PTC C-16-422172 (HP)
- 49 The Global Down Syndrome Foundation (HP, JME)

	medRxiv preprint doi: https://doi.org/10.1101/2024.07.14.24310223; this version posted July 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
50	The Anna and John J. Sie Foundation (JME)
51	The University of Colorado Human Immunology and Immunotherapy Initiative (HI3).
52	
53	Author contributions:
54	Conceptualization: HP, SHS, NE, HJC
55	Methodology: SHS, CC, MMA, KN, BMB
56	Investigation: SHS, CC, MMA, KN, PA, MDG, BMB, JME
57	Supervision: HP, JME
58	Writing—original draft: HP
59	Writing—review & editing: HJC, SHS, CC, MMA, BMB, HP, TDB
60	
61	Declaration of interests:

- 62 HP, TDB, and SHS are inventors on several non-licensed U.S. patents or pending applications owned by the
- 63 University of South Florida or the University of Colorado and related to this research. TDB's contributions to
- 64 this work occurred during his employment at the University of Colorado, and he is now employed and owns
- 65 stock options at Partner Therapeutics. All other authors declare they have no competing interests.

- 67 Declaration of generative AI and AI-assisted technologies
- 68 None used.
- **Data and materials availability:** All data are available in the main text or the supplementary materials.

- 73 Introduction

medRxiv preprint doi: https://doi.org/10.1101/2024.07.14.24310223; this version posted July 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Increasing age is the greatest risk factor for 'natural' age-associated cognitive decline (AACD) and,

74 75 especially in females, for developing Alzheimer's disease (AD), but the mechanisms underlying this connection are unknown¹⁻¹⁰. Neuronal loss and brain atrophy accompany aging and AD and can reasonably 76 be inferred to lead to cognitive deficits ¹¹⁻¹⁴. Increased inflammation is also correlated with AD pathogenesis 77 78 and aging (termed 'inflammaging'), but whether inflammation causes and/or is a response to neurodegeneration is also unknown^{1,8,15-17}. For example, early studies of patients with the inflammatory 79 80 disease rheumatoid arthritis (RA) found that they exhibited a reduced risk of developing AD, which was attributed to their use of non-steroidal anti-inflammatory drugs (NSAIDs). However, studies of other 81 82 inflammatory diseases, such as periodontitis, detected an increase in AD risk, and NSAID treatment in 83 clinical trials showed no benefit to participants with either AD or mild cognitive impairment (MCI) (for discussion see ^{16,18,19}). Evidently, the role of inflammation in aging and neurodegenerative disease is 84 85 complex.

86

87 The identification of biomarkers of brain aging and the underlying mechanism(s) that they reflect are 88 essential to advancing the development and testing of therapies for AD and for the more complex AACD ^{17,20-23}. Here we assessed two proteins that reflect neuronal loss (UCH-L1) and axonal damage (NfL) and find 89 90 that their plasma concentrations become exponentially higher throughout life starting from age 2. 91 Furthermore, astrogliosis, measured by plasma concentrations of GFAP, becomes exponentially higher 92 starting at age 40 and is thus likely to be reactive to rather than causal of neurodegeneration during aging and 93 reflect a positive feedback loop that underlies the exponential nature of the increases in all three biomarkers 94 of brain damage with age. Finally, we report that GM-CSF/sargramostim, a long-approved drug for 95 stimulating immune stem cells in patients with leukopenia, which we previously found to improve cognition 96 and biomarkers of neurodegeneration in a clinical trial of mild-to-moderate Alzheimer's disease, effectively 97 reverses the rate of neuronal loss in trial participants to the very low levels observed in early childhood in the 98 current study. We also found that GM-CSF treatment reduces neuronal apoptosis in the hippocampi of aged medRxiv preprint doi: https://doi.org/10.1101/2024.07.14.24310223; this version posted July 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. TgF344-AD rats, a model that recapitulates all human AD brain neuropathology. These findings in humans

- 99
- 100 and animals add biological significance to the statistically significant finding in the clinical trial.
- 101
- 102 Results

103 **Biomarkers of Neurodegeneration**. To identify biomarkers of neuronal cell loss or damage during brain 104 aging, we focused on UCH-L1 and NfL because of numerous reports that their plasma concentrations are 105 well correlated with neuronal damage in, for example, neurodegenerative disease and traumatic brain injury (TBI)²⁴⁻²⁹. Although UCH-L1 was initially discovered and named as a ubiquitin C-terminal hydrolase, it is 106 107 likely that this is not its primary function, especially in neurons, as cells and animals lacking UCH-L1 are not defective in the ubiquitin proteosome system ^{25,30}. Indeed, UCH-L1 is primarily a brain protein, making up 1-108 5% of the total protein in neurons, with some expression in endocrine tissue ^{25,26}. Suggestions for the 109 110 neuronal function of UCH-L1 include the regulation of energy metabolism and mitochondrial fusion, antioxidant activity, and synaptic activity ^{26,30,31}. Regardless of its function, an increased concentration of 111 112 UCH-L1 in the plasma is a sensitive and rapidly-responding measure of acute neuronal cell 113 damage/degeneration after TBI, and UCH-L1 expression is greatly reduced in the AD brain, possibly due to loss of neurons or neuronal activity ²⁴⁻²⁷. NfL is an intermediate filament protein in neurons and an essential 114 115 component of axons. Traumatic or disease-associated damage to axon tracks leads to the release of NfL into 116 the cerebrospinal fluid (CSF) and ultimately into the plasma where it can be detected as a biomarker of axonal damage in numerous neurodegenerative diseases as well as in TBI ^{25,28,32}. 117

118

119 Plasma concentrations of UCH-L1 are exponentially higher with age from early childhood. Plasma 120 concentrations of UCH-L1, a measure of neuronal cell loss, were assessed in 317 healthy control participants 121 between age 2 and 85 from three observational studies. These included 103 healthy control participants from 122 the Human Trisome Project (HTP) of the Linda Crnic Institute for Down Syndrome (i.e., healthy controls 123 without Down syndrome (DS)), 69 healthy control participants from the University of Colorado Alzheimer's medRxiv preprint doi: https://doi.org/10.1101/2024.07.14.24310223; this version posted July 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. and Cognition Center (CUACC) study of the role of inflammation in AD (termed Bio-AD)¹⁷, and 145

124 healthy control participants from the multiple sclerosis (MS) biomarker study (see demographics in 125 Methods). The assessments were determined using the Quanterix SIMOA[®] platform, which was also used 126 127 previously to assess plasma biomarkers in the "sargramostim/GM-CSF AD trial" in participants with mildto-moderate AD³³. As shown in Figure 1A, plasma UCH-L1 concentrations increase exponentially with age 128 129 across the entire age spectrum, from an estimated 6.22 pg/ml at age 2 to approximately 15.56 pg/ml at age 85 130 (estimated change per year = 1.110%, 95% CI: (0.716%, 1.505%), p = $5.504 \times 10^{(-8)}$). Graphical inspection 131 of the data, and comparison to a spline fit (Supplementary Figure 1A), indicate that a log-linear relationship 132 of UCH-L1 concentrations with age is an excellent fit (Pearson correlation estimate (replicates log averaged) = 0.30, 95% CI: (0.20, 0.40)), which is equivalent to an exponential relationship on the original scale (Figure 133 134 1A and 1B). Interestingly, most of the age-associated increase in plasma concentrations of UCH-L1 occurs 135 in females (Figure 1C, estimated female change per vear = 1.448%, 95% CI: (0.942%, 1.957%), p = 3.635 *136 $10^{(-8)}$; estimated male change per vear = 0.582%, 95% CI: (-0.036%, 1.203%), p=0.0650; sex difference 137 p=0.0342; estimate of the ratio of ratios = 0.99146, 95% CI: (0.98362, 0.99936)). The log plots in Figure 1D and the spline analyses (Supplementary Figure 1B) support the conclusion that the plasma concentration of 138 139 UCH-L1 increases exponentially with age in males and females. Because plasma UCH-L1 is primarily 140 derived from damaged brain neurons, its concentration in plasma provides a minimal estimate of the ongoing 141 neuronal cell death in the brain with age (Supplementary Figure 2).

- 142
- 143
- 144
- 145
- 146
- 147
- 148



149 **Figure 1.**

Figure 1. Plasma UCH-L1 concentrations are higher with advancing age in healthy control participants, especially in females.

152 Concentrations of UCH-L1 in plasma from 314 healthy control participants who were part of either the Crnic Institute Human Trisome Project (n=103), the CUACC Bio-AD longitudinal observational study (n=69), or 153 154 the MS healthy controls biomarker study (n=145) (3 participants lacked usable UCH-L1 data) were 155 compared to the age of the participant. Together, these three healthy control cohorts span ages 2-85. The 156 association between absolute UCH-L1 concentrations and age and the point wise standard errors are shown 157 in (A). The UCH-L1 log plot with point wise standard errors is shown in (B). The data show that plasma 158 UCH-L1 levels are exponentially higher with age across the lifespan (estimated change per year=1.110%, 159 95% CI: (0.716%, 1.505%), $p = 5.504 * 10^{(-8)}$). The effect of sex on the curve is shown in (C), which 160 indicates that the majority of the promotion effect of age on plasma UCH-L1 concentrations are driven by 161 females (estimated female change per year=1.448%, 95% CI: (0.942%, 1.957%), $p = 3.635 * 10^{(-8)}$; 162 estimated male change per year=0.582%, 95% CI: (-0.036%, 1.203%), p=0.0650; sex difference p=0.0342; 163 sex ratio of ratios = 0.99146, 95% CI: (0.98362, 0.99936), p=0.0342). The effect of sex on the UCH-L1 log 164 plot with point wise standard errors is shown in (**D**). The associations between absolute UCH-L1 165 concentrations and age and the point wise standard errors are shown. For the age range of 40-83 years, the 166 area under the curve (AUC) average for the expected UCH-L1 values in males was statistically significantly less than the expected values in females (ratio estimate = 0.792, 95% CI: (0.628, 0.997), p value = 0.0472). 167 168 Because the age effects in the model are linear in the log plot, the AUC average is equivalent to comparing the expected value for males to females at the midpoint of the range, 61.5 years. 169

170

Plasma concentrations of NfL are exponentially higher with age from early childhood. Plasma 171 172 concentrations of NfL, which is released primarily from damaged axons, is commonly used to assess/stage AD, MCI, and the risk of future cognitive decline ^{22,28}. Therefore, we examined the effects of age and sex on 173 174 plasma concentrations of NfL in the 317 healthy control participants. As shown in Figure 2A and 2B, plasma 175 concentrations of NfL were exponentially higher with increasing age in healthy control participants (p < p176 2.220 *10⁽⁻¹⁶⁾), with the slope of the log-transformed curve being greater than that observed for UCH-L1 with increasing age, such that NfL plasma concentrations are higher by 2.469% per cross-sectional year 177 178 (95% CI: (2.225%, 2.714%), p < 2.220 * 10⁽⁻¹⁶⁾). Of note, the 95% confidence intervals for the NfL and 179 UCH-L1 rates of increase are non-overlapping, suggesting a statistically significant difference (alpha=0.05) 180 between the two. The exponential curve of plasma NfL with age showed a trend of being steeper for males 181 than for females (p = 0.0502), with an estimated difference per year of 2.775% (95% CI: (2.388%, 3.164%), 182 $p < 2.220 * 10^{(-16)}$ for males, compared to an estimated difference per year of 2.277% (95% CI: (1.965%), 2.590%), $p < 2.220 * 10^{(-16)}$ for females (Figure 2C); estimate of ratio of ratios = 1.00487, 95% CI: 183 184 (1.00000, 1.00976), p=0.0502.







Figure 2. Plasma concentrations of NfL are exponentially higher with age in healthy control participants.

Concentrations of NfL in plasma samples from the 317 healthy control participants who were part of the Human Trisome Project (HTP) (n=103), the Bio-AD longitudinal observational study (n=69), or the MS healthy controls biomarker study (n=145) were compared to the age and sex of the donor. The data show that plasma concentrations of NfL are exponentially higher with age across the entire lifespan (p < 2.220 *10^(-16)). The association between absolute NfL concentrations and age and the point wise standard errors are shown in (**A**) and the log plot is shown in (**B**) (estimated change per year=2.469% per year, 95% CI:

(2.225%, 2.714%), p < 2.220 *10⁽⁻¹⁶⁾). Separate plots for plasma concentrations of NfL in males and 216 217 females are shown in (C). For NfL, the exponential rate of change determined cross-sectionally was 218 marginally statistically non-significantly greater in males than in females (ratio of ratios = 1.00487, 95% CI: (1.00000, 1.00976), p = 0.0502); estimated change per year was 2.775% (95% CI: (2.388%, 3.164%), p < 219 220 2.220 *10⁽⁻¹⁶⁾) in males, compared to 2.277% per year (95% CI: (1.965%, 2.590%), $p < 2.220 *10^{(-16)}$) 221 in females. When comparing the log linear fit to splines for the association of NfL with age and sex in 222 healthy controls (replicates averaged), the graph suggests that the rate of increase accelerates somewhat with 223 older age, but a linear relationship is still an excellent approximation for all healthy controls 224 (Supplementary Figure 1C) and when males and females are examined separately (Supplementary Figure 225 1D).

226

Plasma concentrations of GFAP are exponentially higher from age 40. GFAP is upregulated in activated 227 228 astrocytes, and its increased concentration in CSF or plasma is a marker of reactive gliosis in aging, neurodegenerative disease, and TBI ^{17,27,34}. Both females and males in our combined three cohorts that span 229 230 ages 2-85 showed an apparent overall exponential age effect for plasma GFAP concentrations (Figure 3A, 231 **3B, and 3C**) for both sexes (estimated female change per year=1.803%, 95% CI: (1.431%, 2.177%), $p < 10^{-10}$ $2.220 \times 10^{(-16)}$; estimated male change per year=1.496%, 95% CI: (1.037%, 1.957%), p = 4.240 $\times 10^{(-16)}$ 232 233 10)), with no significant difference between males and females. Interestingly, spline modeling of the plasma 234 levels of GFAP (replicates averaged) show a deviation from linearity in the log plots in that the GFAP levels show a U shape with a decline from age 2 to 25, a constant rate, and then an exponential rise only starting 235 236 from approximately age 40 (Figure 3D). The U shape spline plot is apparent for both sexes with females 237 apparently rising slightly faster with age (Figure 3E). These findings indicate that brain 238 astrogliosis/neuroinflammation follows and thus is likely a reaction to the earlier and ongoing age-associated 239 neurodegeneration.

240

241 **Figure 3.**







244

Figure 3. Plasma concentrations of GFAP are exponentially higher with age in healthy control participants.

247 Concentrations of GFAP in plasma samples from the 317 healthy control participants who were part of the 248 Human Trisome Project (HTP) (n=103), the Bio-AD longitudinal observational study (n=69), or the MS 249 healthy controls biomarker study (n=145) were compared to the age and sex of the donor. The data show that 250 plasma concentrations of GFAP are exponentially higher with age across the entire lifespan (p < 2.220) 251 *10⁽⁻¹⁶⁾). The association between absolute GFAP concentrations and age and the point wise standard 252 errors are shown in (A) and the log plot is shown in (B) (estimated change per year=1.696%, 95% CI: 253 (1.404%, 1.989%), p < 2.220 *10⁽⁻¹⁶⁾). Separate plots for plasma concentrations of GFAP in males and 254 females are shown in (C). Both sexes showed an exponential age effect for GFAP (estimated female change 255 per year=1.803%, 95% CI: (1.431%, 2.177%), p < 2.220 *10^(-16); estimated male change per year=1.496%, 95% CI: (1.037%, 1.957%), p = 4.240 * 10^(-10)), but there was not a statistically significant 256 257 difference in age effect between the sexes (ratio of ratios = 1.00302, 95% CI: (0.99720, 1.00889), p=0.3088). 258 We also compared the log linear fit to splines for the biomarker association with age in the healthy controls 259 (replicates averaged) in (**D**). The deviance test for comparing spline model to the null hypothesis of linear: p 260 value $< 2.2 * 10^{(-16)}$. The evidence is against linearity with a large sample, with the graph suggesting 261 something of a U shape with GFAP concentrations accelerating significantly after age 40. A spline plot by 262 sex in the healthy controls (replicates averaged) also suggests a U shape with GFAP concentrations 263 accelerating significantly after age 40 in (E). Deviation from linearity is evidenced in the data from males 264 and females, with females apparently rising slightly faster with age.

265

266 Correlation analyses of plasma measures of age-associated brain degeneration. Figure 4 shows the

267 correlations of the measures of neurodegeneration (UCH-L1, NfL) and astrogliosis (GFAP) for all healthy

268 control participants from age 2 to 85. All three measures (UCH-L1:NfL, UCH-L1:GFAP, and NfL:GFAP)

medRxiv preprint doi: https://doi.org/10.1101/2024.07.14.24310223; this version posted July 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. are highly correlated with each other (P< 10^(-11)), indicating that brain aging across the lifespan reflects

- parallel increases in neurodegeneration, both cellular and axonal, and astrogliosis/inflammation.
- Figure 4.



Figure 4: Correlations between plasma biomarkers of neurodegeneration and astrogliosis, UCH-L1, NfL, and GFAP.

Log transformed replicate measures of UCH-L1, NfL, and GFAP from all normal control participants, age 2-85, were averaged over replicates and subjected to Pearson and Spearman correlation analyses and found to be highly correlated with each other. (**A**) UCH-L1:NfL, PC=0.37951, 95% CI: (0.280616, 0.470436), P = $3.157 \times 10^{(-12)}$; (**B**) UCH-L1:GFAP, PC=0.42263, 95% CI: (0.327250, 0.509477), P = 4.441 \times 10^{(-15)}; and (**C**) NfL:GFAP PC=0.63743, 95% CI: (0.567089, 0.698536), P < 2.220 $\times 10^{(-16)}$.

305 Comparisons of plasma measures of age-associated brain neurodegeneration and inflammation in

306 MCI due to AD, mild-to-moderate AD, and healthy controls.

307 AD dementia and its precursor, MCI due to AD, are both strongly associated with age and are accompanied by neurodegeneration and astrogliosis in the brain ¹⁷. Having established full age curves for plasma markers 308 309 of neurodegeneration (UCH-L1 and NfL) and astrogliosis/inflammation (GFAP), we compared these to the 310 age-associated concentrations of NfL, GFAP, and UCH-L1 in plasma samples from the 32 participants with 311 MCI due to AD from the Bio-AD study (MCI) and in plasma samples from 36 participants with mild-to-312 moderate AD from our previously published GM-CSF/sargramostim clinical trial at baseline (Baseline AD GM-CSF Study Pooled)³³ (Figure 5). A diagnosis of MCI or mild-to-moderate AD was associated with 313 314 higher overall levels of both NfL (Figure 5A) and GFAP (Figure 5B) compared to age-matched healthy 315 control participants. NfL concentrations were higher in participants with mild-to-moderate AD than in 316 participants with MCI, while there was no significant difference in GFAP concentrations between 317 participants with mild-to-moderate AD and participants with MCI at 67.8 years, which is the mean age for 318 the sargramostim/GM-CSF-treated mild-to-moderate AD participants (AD/HC estimate age 67.8: NfL: ratio 319 estimate = 1.852, 95% CI: (1.514, 2.265), p = 2.201×10^{-7} ; GFAP: ratio estimate = 1.842, 95% CI: 320 (1.539, 2.203), p = 4.169 * 10⁽⁻⁹⁾; MCI/HC estimate age 67.8: NfL: ratio estimate = 1.362, 95% CI: (1.104, 321 1.682), p=0.0050; GFAP: ratio estimate = 1.948, 95% CI: (1.473, 2.577), p = 2.230×10^{-5} ; AD/MCI 322 estimate age 67.8: NfL: ratio estimate = 1.359, 95% CI: (1.042, 1.772), p=0.0242; GFAP: ratio estimate = 0.945, 95% CI: (0.699, 1.278), p=0.7091), as expected from previous studies 17,28 . Interestingly, the plasma 323 324 concentration of NfL showed age-associated higher levels in the participants with mild-to-moderate AD 325 (2.714% per year, 95% CI: (0.625%, 4.847%), p=0.0122) (Figure 5A), whereas GFAP plasma

326	concentrations did not show age-associated higher levels in the participants with mild-to-moderate AD (-
327	0.030% per year, 95% CI: (-2.061%, 2.042%), p=0.9761). Plasma concentrations of both NfL and GFAP
328	showed age-associated higher levels for MCI (NfL: 4.138% per year, 95% CI: (1.664%, 6.672%), p=0.0017;
329	GFAP: 3.466% per year, 95% CI: (0.170%, 6.871%), p=0.0398) (Figure 5B). There were no statistically
330	significant differences among the age slopes for healthy controls, AD, and MCI for either NfL or GFAP.

331

332 UCH-L1 levels in the participants with MCI due to AD are higher overall than the plasma UCH-L1 333 concentrations of the healthy control participants at the mean age for the sargramostim/GM-CSF-treated 334 mild-to-moderate AD participants, 67.8 years (ratio estimate = 1.440, 95% CI: (1.101, 1.885), p=0.0088), 335 whereas the plasma UCH-L1 concentrations of the mild-to-moderate AD participants at the baseline visit 336 prior to GM-CSF/sargramostim treatment are approximately the same as those of the healthy control 337 participants (ratio estimate = 0.967, 95% CI: (0.798, 1.171), p = 0.7257) (Figure 5C). UCH-L1 338 concentrations in MCI were higher than in mild-to-moderate AD at 67.8 years (ratio estimate = 1.490, 95%) 339 CI: (1.133, 1.961), p=0.0052). UCH-L1 increased for participants with mild-to-moderate AD by an estimated 340 2.420% per year of age (95% CI: (0.783%, 4.083%), p=0.0054), while the estimated age-associated increase 341 for MCI is marginally statistically non-significant (estimate = 2.499% per year, 95% CI: (-0.446%, 5.531), 342 p=0.0941), possibly because it is underpowered with the modest sample size. There were no statistically 343 significant differences among the age slopes for healthy controls, mild-to-moderate AD, and MCI for UCH-344 L1 (interaction test p value = 0.2040). This analysis suggests that during the age-associated progression to 345 mild-to-moderate AD, plasma levels of GFAP and NfL, markers of astrogliosis and axonal damage, 346 respectively, rise with the level of cognitive decline, but UCH-L1 measures of neuronal cell damage are 347 higher early during the MCI phase and are then closer to normal at the mild-to-moderate AD stage, perhaps 348 due to lower neuronal loss, or to lower release of UCH-L1 from neurons.

- 349
- 350
- 351



Figure 5. Comparisons between plasma NfL, GFAP, and UCH-L1 concentrations and age in participants with MCI due to AD, participants with mild-to-moderate AD, and healthy control participants.

We compared the concentrations of NfL, GFAP, and UCH-L1 in plasma samples from participants assessed as having MCI due to AD as part of the CUACC Bio-AD longitudinal observational study (n=32) (MCI), and gatticipants from the Phase II, double-blind, randomized, placebo-controlled trial with recombinant human GM-CSF (the "sargramostim/GM-CSF AD trial") at baseline prior to treatment with sargramostim/GM-CSF or placebo (Baseline AD GM-CSF Study Pooled), and the corresponding segment of

the age curve from the 317 healthy control participants who were part of either the Crnic Institute Human Trisome Project (HTP) (n=103), the CUACC Bio-AD longitudinal observational study (n=69), or the MS healthy controls biomarker study (n=145). The mean age for the sargramostim/GM-CSF-treated mild-tomoderate AD participants was 67.8 years.

- 387 (A) Plasma NfL concentrations in participants with MCI or mild-to-moderate AD are higher, correlating with 388 disease progression, than in age-matched healthy control participants and also show an increase with age 389 (MCI geometric mean estimate 15.27 pg/ml (95% CI: (12.54, 18.58) pg/ml) at age 67.8; mild-to-moderate 390 AD geometric mean estimate of 20.75 pg/ml (95% CI: (17.22, 25.01) pg/ml) at age 67.8 and baseline 391 calibrated compared to age-matched healthy control participants (geometric mean estimate of 11.21 pg/ml 392 (95% CI: 10.36, 12.13) pg/ml; MCI/HC ratio estimate = 1.362, 95% CI: (1.104, 1.682), p=0.0050; AD/HC393 ratio estimate = 1.852, 95% CI: (1.514, 2.265), p = 2.201×10^{-7}). NfL was statistically significantly 394 higher in AD than in MCI at 67.8 years (ratio estimate = 1.359, 95% CI: (1.042, 1.772), p=0.0242). The 395 estimated exponential change in plasma NfL for MCI was 4.138% per year (95% CI: (1.664%, 6.672%), 396 p=0.0017) and for mild-to-moderate AD was 2.714% per year (95% CI: (0.625%, 4.847%), p = 0.0122). The 397 differences between the MCI or mild-to-moderate AD rate of change and healthy control rate of change were 398 not statistically significant for NfL, but the power of the comparison test is limited because of the small 399 sample size of the mild-to-moderate AD group (interaction test p value = 0.3953).
- 400 (B) Participants with MCI or mild-to-moderate AD exhibit a higher concentration of plasma GFAP (MCI: 401 geometric mean estimate = 191.78 pg/ml, 95% CI: (147.18, 249.89) pg/ml) (AD: geometric mean estimate of 402 181.28 pg/ml (95% CI: (155.40, 211.46) pg/ml) at the sargramostim/GM-CSF mean age of 67.8 and baseline 403 calibrated) compared to age-matched healthy control participants (geometric mean estimate of 98.43 pg/ml 404 (95% CI: (89.51, 108.24) pg/mL; MCI/HC ratio estimate = 1.948, 95% CI: (1.473, 2.577), p = 2.230×10^{-1} 405 5); AD/HC ratio estimate = 1.842, 95% CI: (1.539, 2.203), p = 4.169×10^{-9}). GFAP levels for mild-to-406 moderate AD and MCI were similar at 67.8 years (AD/MCI ratio estimate = 0.945, 95% CI: (0.699, 1.278), 407 p=0.7091). The levels for the MCI participants increase with age (estimated change per year = 3.466%, 95%) 408 CI: (0.170%, 6.871%), p=0.0398), but the levels do not change for the mild-to-moderate AD participants 409 (estimated change per year = -0.030%, 95% CI: (-2.061%, 2.042%), p = 0.9761). The differences between 410 the MCI or AD rate of change and healthy control rate of change were not statistically significant for GFAP, 411 but the power of the comparison test is limited because of the small sample size of the mild-to-moderate AD 412 group (interaction test p value = 0.1482).
- 413 (C) The mean of plasma UCH-L1 concentrations in participants with MCI due to AD is statistically 414 significantly higher (ratio estimate = 1.440, 95% CI: (1.101, 1.885), p=0.0088, at mean age of 67.8 years) 415 than for healthy control participants, indicating the initiation of neurodegeneration beyond that caused by 416 normal aging alone. Notably, the mean plasma concentrations of UCH-L1 at baseline for mild-to-moderate 417 AD participants in the sargramostim/GM-CSF AD trial are similar to the concentrations in the healthy 418 control participants at the corresponding age (ratio estimate = 0.967, 95%: (0.798, 1.171), p = 0.7257), 419 possibly because neuronal loss has reduced the numbers of neurons available to release UCH-L1, but the 420 increase with age remains statistically significant (estimated change per year = 2.420%, 95% CI: (0.783%, 421 4.083%), p=0.0054). The estimated slopes of the association between plasma UCH-L1 concentrations and 422 age in the participants with MCI due to AD (estimated change per year=2.499%, 95% CI: (-0.446%, 423 5.531%), p = 0.0941) or with mild-to-moderate AD are between 2 to 2.5, which is the slope of the correlation 424 between plasma UCH-L1 concentrations and age in the healthy control participants in Figure 1 (estimated 425 change per year=1.110%, 95% CI: (0.716%, 1.505%), p = 5.504 * 10^(-8)), but the differences are not 426 statistically significant, most likely due to the small numbers of participants in the MCI due to AD group and 427 in the mild-to-moderate AD group (interaction test p value = 0.2040).
- 428

medRxiv preprint doi: https://doi.org/10.1101/2024.07.14.24310223; this version posted July 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Treatment of AD trial participants with sargramostim/GM-CSF reverses the rate of neuronal loss to

430 Treatment of AD trial participants with sargramostim/GM-CSF reverses the rate of neuronal loss to

431 that of normal controls many decades younger.

432 In addition to identifying potential mechanisms of brain aging, age-associated biomarkers may be used to 433 assess the efficacy of interventions that may slow or even halt the aging process. We have previously 434 discovered GM-CSF/sargramostim as a potential treatment for AD whose likely mechanisms of action may 435 include targeting the aging process in the brain. Specifically, based on early studies showing that RA patients 436 had a reduced risk of developing AD, we hypothesized that this protection might be due to a physiological reaction against RA's associated inflammation, with the beneficial side effect of reducing the risk of AD, 437 438 which exhibits brain inflammation. We tested our hypothesis and found that treatment of a mouse model of 439 AD with GM-CSF, an immune system stimulating/modulating cytokine that stimulates the proliferation of 440 immune stem cells in both the bone marrow and the brain and is upregulated in the plasma of RA patients, 441 reduced brain amyloid levels by half, increased brain synaptophysin levels, and restored memory to normal after a few weeks of subcutaneous administration³⁵. This finding was subsequently confirmed in a different 442 mouse model of AD ³⁶. Furthermore, we and others have shown that GM-CSF treatment also improves 443 444 cognition and neuronal function in aged wild-type mice, indicating that the beneficial effects of GM-CSF on the brain are not exclusively targeting AD pathology but also extend to normal aging 35,37,38 . 445

446

447 Building on this foundation, we recently completed a Phase II, double-blind, randomized, placebo-controlled trial of human recombinant GM-CSF (sargramostim) (250 mcg/m²/day subcutaneous injection, five 448 days/week for three weeks) in participants with mild-to-moderate AD³³. Treatment with sargramostim led to 449 450 improved scores in the Mini-Mental State Exam (MMSE) by almost two points (compared to baseline and to 451 placebo) and moved the concentrations of AD-associated plasma biomarkers-amyloid, total Tau-toward 452 normal. This was the first full phase II trial of an intervention that showed improvement, instead of slowing, 453 in AD patients ³³. Interestingly, the largest change in a measure of AD neuropathology at the end of 454 treatment was in plasma UCH-L1 concentrations, which had decreased in the sargramostim-treated group by medRxiv preprint doi: https://doi.org/10.1101/2024.07.14.24310223; this version posted July 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. 40% compared to baseline (p=0.0017) and by 42% compared to placebo (p=0.0019)³³. However, in that

40% compared to baseline (p=0.00ľ7) and by 42% compared to placebo (p=0.0019) ³³. However, in that 456 study we had no way to assess the true impact of the reduction of plasma UCH-L1 concentrations compared 457 to cognitively normal individuals. Here, we therefore compared the previous results to the age curves for 458 UCH-L1 shown in **Figure 1** to determine how effective sargramostim/GM-CSF treatment was in reducing 459 this measure of neuronal loss with aging.

460

461 The plasma concentrations of UCH-L1 in mild-to-moderate AD participants at baseline and at the end of 462 treatment with sargramostim/GM-CSF are plotted with the data from healthy control participants in Figure 463 6A and show that the absolute values of plasma UCH-L1 are greatly reduced after sargramostim/GM-CSF 464 treatment (ratio estimate = 0.497, p=0.0008). Indeed, sargramostim/GM-CSF treatment reduces the 465 concentrations of UCH-L1 in plasma of trial participants to an average level far below those of similarly 466 aged healthy control participants (ratio estimate = 0.502, p=0.0019), and equivalent to that found in healthy 467 control participants six decades younger (Figure 6A). For example, a 67.8-year-old mild-to-moderate AD 468 participant treated with sargramostim/GM-CSF would have had a plasma UCH-L1 concentration of 6.47 469 pg/ml (geometric mean, 95% CI: (4.45, 9.39) pg/ml, not baseline calibrated - sargramostim/GM-CSF 470 baseline only), which is equivalent to that expected of a 5.4-year-old healthy control participant, based on our 471 cross-sectional data. This conclusion required the comparison of the plasma UCH-L1 data from the 472 sargramostim treatment trial to the new data shown in **Figure 1**. The rate of loss of UCH-L1-positive 473 neurons during sargramostim/GM-CSF treatment in the clinical trial is shown in **Figure 6B**: the three-week 474 treatment resulted in a reduction in the rate of UCH-L1 neuron deaths by 2.62 million neuron deaths per year 475 per person (95% CI: (1.53, 3.71) million).





Figure 6. Treatment of participants with mild-to-moderate AD with sargramostim/GM-CSF reduces plasma UCH-L1 concentrations and neuronal loss to levels seen in healthy control participants six and a half decades younger with an average comparable to that of 5.2-year-old healthy control participants.

483 Association plots and point wise standard errors are shown for the participants with mild-to-moderate AD 484 from the Phase II, double-blind, randomized, placebo-controlled trial with recombinant human GM-CSF (the 485 "sargramostim/GM-CSF AD trial") at baseline before they were treated with sargramostim/GM-CSF (AD 486 Untreated - GM-CSF Baseline, n=18) or after they were treated with sargramostim/GM-CSF (AD GM-CSF 487 Treatment, n=18) together with the correlation curve for healthy control participants from Figure 1 (A). The 488 comparison shows that treatment of participants with mild-to-moderate AD with sargramostim/GM-CSF 489 leads to absolute UCH-L1 values that are greatly reduced compared to their starting (baseline) levels (ratio 490 estimate = 0.497, 95% CI: (0.350, 0.705), p=0.0008). Furthermore, sargramostim/GM-CSF treatment reduces 491 expected plasma UCH-L1 concentrations far below those of similarly aged healthy control participants (ratio 492 estimate = 0.502, 95% CI: (0.341, 0.741), p=0.0019 at a mean age of 67.8 years), and leads to a geometric 493 average plasma UCH-L1 level that sets a 67.8-year-old mild-to-moderate AD participant approximately 494 equal to that expected of a 5.4-year-old healthy control participant (horizontal dotted line). The healthy 495 control age equivalent of the plasma concentrations of UCH-L1 after GM-CSF treatment ranged from around 496 4 years old for 67-year-old mild-to-moderate AD participants to around 32 years old for 80-year-old mild-to-497 moderate AD participants. The reduced plasma UCH-L1 levels associated with GM-CSF-treatment of mild-498 to-moderate AD participants are statistically significantly lower than those of all healthy control participants 499 above approximately age 37.8 (vertical dot-dash line) but are statistically indistinguishable (p>0.05) from healthy control participants younger than age 37.8. The plots calculated for neuron loss are shown in (**B**), 500 501 which indicate that this three-week treatment resulted in a reduction in the rate of neuron deaths by 2.62 502 million neuron deaths per year per person (95% CI: (1.53, 3.71) million).

- 503
- 504

medRxiv preprint doi: https://doi.org/10.1101/2024.07.14.24310223; this version posted July 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. GM-CSF treatment reverses neuronal apoptosis in hippocampi of AD rats. To investigate the

505 mechanism by which GM-CSF treatment reduces plasma concentrations of UCH-L1 and thus neuronal 506 507 death, we examined aged TgF344-AD rats (18-20 months of age), a model of AD that shows the complete brain pathology of human AD (amyloid and Tau deposition and neuronal loss)³⁹. TgF344-AD rats were 508 509 treated with recombinant rat GM-CSF or saline placebo for five weeks, and their brains were assessed by 510 immunohistochemical staining for Caspase-3, a marker of apoptosis that is increased in humans and animal models with AD, and during aging ^{40,41}. Data from the treated TgF344-AD rats were also compared to age-511 512 matched wild-type (WT) control F344 rats. As shown in Figure 7, aged TgF344-AD rats treated with saline 513 exhibited large numbers of Caspase-3-positive cells in the CA1, CA3, and dentate gyrus/hilus regions of the 514 hippocampus compared to WT F344 rats. GM-CSF treatment of aged TgF344-AD rats significantly reduced 515 the elevated number of Caspase-3-positive cells compared to placebo-treated TgF344-AD rats, almost 516 reaching the low number observed in the untreated WT F344 rats. Notably, the vast majority of Caspase-3-517 positive cells in the TgF344-AD rats were neurons (approximately 95%) based on co-staining for the MAP2 518 neuronal marker (data not shown). These results indicate that the statistically significant reduction in plasma 519 UCH-L1 in the sargramostim/GM-CSF-treated human AD participants is likely reflecting the biologically 520 significant prevention of AD-associated neuronal apoptosis.

521 522

523 **Figure 7.**



Figure 7. Treatment with GM-CSF reduces neurodegeneration and neuronal cell death in a rat model of AD.

Aged male TgF344-AD rats (18-20 months), a model of AD that overexpresses human A β peptide ³⁹, were treated with GM-CSF or placebo for five weeks as described, and the levels of neuronal damage were assessed by immunohistochemical staining for Caspase-3 (red) together with DAPI staining (blue), followed by blinded counting of Caspase-3-positive cells. Arrowheads in the inserts indicate Caspase-3-positive cells. The numbers of Caspase-3-positive cells were determined in the CA1 (A-C), the CA3 (D-F), and the dentate gyrus/hilus (G-I) regions of the hippocampus in age-matched F344 male wild-type (WT) rats (A,D,G), TgF344-AD rats injected with saline at the end of treatment (B,E,H), and TgF344-AD rats treated with GM-

573 CSF at the end of treatment (C,F,I). Quantitative analyses showed a significantly higher number of Caspase-3-positive cells in all three regions of TgF344-AD rats injected with saline compared to age-matched WT rats 574 575 (p values as indicated), which decreased significantly with GM-CSF treatment (p values as indicated; J-L). For each bar, data are represented as mean +/- SEM for separate groups of mice. Statistical significance was 576 577 determined by the unpaired Student's t-test for comparison between groups. Scale bar: 100 µm (20X magnification). All experiments were repeated 2-6 times with similar results (n=5 for WT rats, n=7 for 578 579 Tg344-AD rats injected with saline, and n=7 for Tg344-AD rats treated with GM-CSF). Notably, the vast majority of Caspase-3-positive cells in the analyzed regions in the TgF344-AD rats were neurons 580 581 (approximately 95%) as determined by co-staining for the MAP2 neuronal marker (data not shown). 582

583

584 Discussion

585

The identification of biomarkers of brain aging is an area of active investigation, and our study has important strengths over previous reports. For example, the identification of biomarkers of aging in different organs, including brain, has been reported recently ²⁰. However, that study examined a limited age spectrum and thus does not give insights into when brain aging begins, as we have found. Furthermore, the 'cognition brain' markers examined in that study related more to neuronal function than to neuronal loss or damage per se. Most importantly, previous studies have not shown an **exponential** age-associated elevation in markers of brain damage across the life span that our data show.

593

594 An exponential increase in any product of a biological process implies the existence of at least one positive 595 feedback loop that accelerates the process. Our finding of exponential rises in the cross-sectionally assessed 596 first markers of brain degeneration. of neuron loss and axon damage. and then of 597 astrogliosis/neuroinflammation with age and their strong correlations with each other evidenced in Figures 598 1-4 implies the existence of such a positive feedback loop in the process of brain aging. Specifically, the rise 599 in neuron loss and axon damage evident in plasma from early childhood is likely to induce 600 gliosis/inflammation to phagocytose the resulting debris, which would initiate the 'inflammaging' cascade, 601 resulting in a vicious cycle of more neuronal damage and death and more inflammation.

Notably, the positive feedback loop involving neuronal loss/damage and inflammation in brain aging
throughout life that the new data demand includes the same components as the already-established positive

medRxiv preprint doi: https://doi.org/10.1101/2024.07.14.24310223; this version posted July 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. feedback loop that comes into play later, in the development of AD. Specifically, we and others have found

604 that gliosis/neuroinflammation in AD increases the expression of cytokines that lead through several steps to 605 increased production of A β peptides and their polymerization into neurotoxic oligomers and filaments. The 606 607 resulting AB oligomers, in turn, further increase neuroinflammation through further activation of microglia and astrocytes ^{15,16,42-44}. Such positive feedback loops are ideal targets for developing inhibitors of pathogenic 608 pathways. The other key discovery of our investigation here—that a long-approved immune stem cell 609 610 stimulating drug, GM-CSF/sargramostim, can be repurposed to reverse age-associated neuronal loss in both 611 human research participants and an animal model of AD—illustrates the benefit of blocking a key step in the 612 feedback loop of age-associated brain degeneration.

613

614 In sum, our findings allow several novel conclusions to be drawn:

1. The concentrations of two plasma biomarkers of neuronal damage, UCH-L1 (Figure 1) and NfL
(Figure 2), are exponentially higher with increasing age in healthy control participants, indicating
that normal brain aging is a process that starts in early childhood, continues throughout life, and
becomes behaviorally apparent only later in life, probably as the neuronal damage overcomes
functional redundancy and resiliency.

620 2. The higher levels of neuron-derived UCH-L1 concentrations in plasma with age in healthy control 621 participants imply an exponential increase in the loss of, or severe damage to, neurons (estimated as a 622 loss of roughly several hundred million neurons over a lifespan, or a minimum of 338 million neuron 623 deaths per person in the sex pooled model (Supplementary Figure 2) and also provides an additional 'N' measure for the AD 'AT(N)' assessment tool. Presumably, neurogenesis, which has also been 624 shown to occur throughout life, replaces some of the neurodegeneration ⁴⁵. Neuronal loss may be 625 larger in specific brain regions, such as the hippocampus, which is relatively small and plays a key 626 627 role in learning and memory.

3. Based on cross-sectional data, the elevations in the concentrations of the plasma biomarkers of neuronal damage, UCH-L1 and NfL, in healthy control participants occur earlier than the increase in astrogliosis (GFAP), which accelerates significantly after age 40 (**Figure 3**), indicating that astrogliosis and its attendant inflammation ('inflammaging') are likely to be both a response to, and an accelerator of, the age-related neuronal damage, rather than an initiating cause. Indeed, this acceleration is evidence of a positive feedback loop that explains the exponential feature of the ageassociated increase in all three biomarkers and of the age-associated risk of AD.

- 4. The higher levels in the measures of neuronal damage and reactive astrogliosis that coincide with
 increasing age in healthy control participants are highly correlated with each other and may underlie
 the enhanced risk of developing AD and other neurodegenerative diseases with increased age (Figure
 4).
- 5. Because plasma concentrations of NfL (Figure 5A) and GFAP (Figure 5B) are higher in participants
 with MCI and mild-to-moderate AD compared to healthy control participants, they appear to reflect
 active AD-associated injury, with NfL levels being higher after the MCI to AD progression. In
 contrast, plasma concentrations of UCH-L1 were higher in participants with MCI than in healthy
 control participants or participants with mild-to-moderate AD (Figure 5C), which may reflect greater
 leakage from damaged neuronal cell bodies early in the disease process compared to healthy aging
 brains.
- 646
 6. The higher age-associated levels in plasma concentrations of UCH-L1 as a measure of greater
 647 neuronal cell loss in females (Figure 1C and 1D) should be further explored to clarify whether this
 648 explains or contributes to their increased risk for age-associated neurodegenerative diseases such as
 649 AD.
- Although the standard errors of the mean for the concentration versus age curves for all threebiomarkers are very tight across the lifespan, there is variance between individuals. Such variance

medRxiv preprint doi: https://doi.org/10.1101/2024.07.14.24310223; this version posted July 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. may reflect increased risk or resilience to the development of AD or AACD caused by genetic

- may reflect increased risk or resilience to the development of AD or AACD caused by genetic
 variants such as *APOE4* alleles ⁴³, lifestyle, environment, or other as-yet unidentified factors¹⁰.
 Higher plasma concentrations of UCH-L1 in an individual compared to the expected age-associated
 level of the healthy control participant curve may serve as a predictive biomarker for the future
 development or onset of MCI (Figure 5C).
- 657

Traditional treatments for AD (e.g., cholinesterase inhibitors and memantine) provide only marginal short-658 659 term benefits by improving acetylcholine neuronal transmission or modulating excitotoxicity, but they do not modify or target the disease mechanism. The recently FDA-approved anti-A\beta/amyloid monoclonal 660 661 antibodies, aducanumab, lecanemab, and donanemab remove amyloid deposits effectively in clinical trials, 662 but they may only slow progressive cognitive decline and can lead to amyloid-related imaging abnormalities (ARIAs: brain edema and micro-hemorrhages) and have been linked with smaller brain volumes ^{46,47}. 663 664 Because most current approaches to AD therapy target AD pathologies in symptomatic adults, none are 665 designed or expected to address the contribution of aging to the development of AD.

666

667 In contrast to other potential treatments for AD, sargramostim/GM-CSF is also beneficial in normal AACD 668 mouse models and for many neurological injuries and diseases without associated AD pathology, for example in animal models of stroke, TBI, and Parkinson's disease ⁴⁸⁻⁵¹, in humans with chemobrain ⁵², and in 669 a preliminary clinical trial in participants with Parkinson's disease ⁵³. Its broad therapeutic applicability may 670 671 be related to the ability of GM-CSF to cross the blood-brain barrier, to be both neuroprotective and anti-672 apoptotic, to stimulate arteriogenesis and blood flow, to promote axon preservation/regeneration and neuronal plasticity, and to induce the proliferation of neural stem cells ^{51,54-58} (for more references and 673 discussion see ¹⁶). The finding that sargramostim/GM-CSF treatment in participants with mild-to-moderate 674 675 AD in the completed Phase II trial led to reduced plasma concentrations of UCH-L1, but not of NfL or 676 GFAP, may be due to the very short treatment period of three weeks. In TBI, plasma UCH-L1 levels increase medRxiv preprint doi: https://doi.org/10.1101/2024.07.14.24310223; this version posted July 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. very rapidly, which dynamically reflects neuronal damage, and then return quickly to baseline after the insult

very rapidly, which dynamically reflects neuronal damage, and then return quickly to baseline after the insult ends, whereas NfL and GFAP are long-lived biomarkers that increase more slowly but persist with longer half-lives and would thus be expected to take longer to show a decrease in response to AD interventions such as sargramostim/GM-CSF ⁵⁹. Our current NIH-funded trial of longer-term treatment (six months) with sargramostim/GM-CSF in participants with mild-to-moderate AD (NCT04902703) may reveal a reduction in plasma concentrations of NfL and GFAP later during the treatment period.

683

The finding that three weeks of sargramostim/GM-CSF treatment of participants with mild-to-moderate AD in a Phase II, double-blind, randomized, placebo-controlled trial led to improved performance on a cognitive measure (almost 2 points on MMSE) and changes in plasma levels of markers of AD neuropathology (A β 40, total Tau, and UCH-L1)³³, together with the novel findings reported here, allow the following additional and novel conclusions to be drawn:

689

690 9. Sargramostim/GM-CSF treatment of participants with mild-to-moderate AD and rats that model AD 691 effectively halts neuronal cell loss assessed by the plasma concentration of UCH-L1 (Figure 6) or 692 Caspase-3/apoptosis (Figure 7), respectively.

- Because a reduction in plasma UCH-L1 was a measure of successful treatment of AD participants
 with sargramostim/GM-CSF (³³ and Figure 6), UCH-L1 measures may be a sensitive biomarker for
 testing the efficacy of other AD treatments and therapeutic changes in lifestyle.
- 696

Our finding that GM-CSF treatment significantly reduced the elevated apoptosis in the CA1, CA3, and dentate gyrus/hilus regions of the hippocampus in the TgF344-AD rat model of AD to levels that were close to those of age-matched WT control rats (**Figure 7**) suggest that the ability of GM-CSF to improve cognition as measured by MMSE, to partially normalize the concentrations of amyloid and tau plasma biomarkers, and to greatly reduce the plasma concentrations of the biomarker of neurodegeneration, UCH-L1, in our medRxiv preprint doi: https://doi.org/10.1101/2024.07.14.24310223; this version posted July 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. previously published Phase II clinical trial of participants with mild-to-moderate AD³³ is likely due to a

702 703 reduction in the number of apoptotic cells in the brain. This reduction in apoptosis is likely due in part to 704 suppression of apoptosis itself, which GM-CSF has been shown to effect, which would thus increase total levels of UCH-L1 and its synaptic function in the larger number of remaining neurons ^{31,56,57}. Furthermore, 705 706 we and others have found that apoptotic/damaged brain neurons in neurodegenerative diseases, including 707 AD, are often an uploid, which would lead to substantial changes in gene expression and defects in cellular functions, and that aneuploidy also leads to apoptosis (for review see ⁶⁰). Indeed, cells naturally undergoing 708 709 senescence accumulate with increased age, and their removal with 'senolytic' molecules can reverse some features of aging, including improving cognition in animal models of AD^{42,61-63}. Similarly, through its ability 710 711 to stimulate the production and activity of innate immune phagocytes (i.e., microglia) in the brain, GM-CSF 712 treatment may enhance the removal of damaged, apoptotic, senescent neurons, just as it caused the rapid reduction of neurotoxic amyloid deposits in the brains of GM-CSF-treated AD mice ³⁵ and AD rats 713 714 (manuscript in preparation), thus allowing the remaining neurons to function more effectively. In sum, our 715 mechanistic studies in TgF344-AD rats are consistent with the conclusion that:

716

11. GM-CSF treatment has an anti-apoptotic function and possibly a senolytic function that reduces the
 number of abnormal neurons and thus reverses neuronal defects and cognitive decline due to
 neurodegenerative disease or aging.

720

In participants with mild-to-moderate AD, the benefits of GM-CSF treatment in improving cognition and reducing plasma markers of neuropathology, including plasma concentrations of UCH-L1, is evidently temporary. The disease is ongoing and all markers of neuropathology return to almost pre-treatment levels by 45 days after sargramostim/GM-CSF treatment is halted; yet there is still a statistically significant benefit to cognition as measured by MMSE at 45 days post-treatment compared to the placebo³³. It remains to be determined whether treatment of healthy aged individuals with sargramostim/GM-CSF will reduce agemedRxiv preprint doi: https://doi.org/10.1101/2024.07.14.24310223; this version posted July 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. associated neuronal damage and reverse AACD only with continuous application or whether it may similarly

associated neuronal damage and reverse AACD only with continuous application or whether it may similarly

- confer a more long-lived benefit after treatment is halted.
- 729
- 730 Limitations:
- a) Patients with MCI and dementia due to AD were identified by clinical diagnosis, not confirmed with
 CSF markers or PET. There were no cutoffs used. Thus, we could not categorize participants into
 A/T/N positivity. Although plasma AD biomarkers are increasingly used, future studies to confirm
 our findings would benefit from an analysis of CSF samples or from the use of mass spectrometry to
 analyze plasma biomarkers.
- b) Pooled data were obtained from cross-sectional/baseline assessments from different studies with
 different inclusion/exclusion criteria, which is also a strength. Caution is warranted in interpreting
 longitudinal *change* in outcomes, as we cannot rule out cohort effects and resulting bias. Future
 studies should assess these biomarkers longitudinally across the lifespan, and/or pool studies with
 harmonized recruitment/enrollment techniques to confirm the results.
- c) High CVs in UCHL-1 measures may impact the clinical application of these findings, with cutoffs.

742

743 Methods

744 Experimental Design

745 Participants: All human subjects research was approved by the Colorado Multiple Institutional Review 746 Board (COMIRB). Specifically, we analyzed healthy control plasma samples from three different studies. Healthy control participants (n=317) who were part of the Crnic Institute Human Trisome Project (HTP, 747 748 n=103; age range: 2-61 years; 54% female) (COMIRB #15-2170; NCT0284108; Dr. Espinosa), the 749 University of Colorado Alzheimer's and Cognition Center (CUACC) Bio-AD longitudinal observational study (n=69; age range: 53-83; 70% female) (COMIRB #15-1774; Dr. Bettcher), or the multiple sclerosis 750 751 (MS) healthy controls biomarker study (termed Nair) (n=145; age range: 16-86; 64% female; 3 participants 752 lacked usable UCH-L1 data) (COMIRB #21-3703; Dr. Nair). See demographics in Supplementary Table 1. 753 The HTP is focused on studying biomarkers and clinical features of people with Down syndrome (DS) and includes typical control participants without DS⁶⁴, and the CUACC Bio-AD study is focused on studying the 754 effect of inflammation on the development of AD¹⁷. The Nair MS biomarker study is investigating 755 756 biomarkers associated with MS and includes healthy control participants. Together, these three healthy 757 control cohorts span ages 2-85.

758

Using three community-dwelling healthy control cohorts that are diverse and heterogenous with a wide range of ages adds confidence to the cross-sectional measures of the plasma biomarkers. If different populations had different levels and slopes of a marker with age, then pooling them would be averaging them and would cause a deviation away from linearity across the full age range, with parametric linear fit trying to smooth it out. However, there is no appreciable deviation from linearity for UCH-L1 or NfL when examined with the spline fits ⁶⁵ (**Supplementary Figure 1**). GFAP measures across age are more complex, increasing exponentially only after age 40.

766

medRxiv preprint doi: https://doi.org/10.1101/2024.07.14.24310223; this version posted July 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Participants assessed as having mild cognitive impairment (MCI) due to AD (n=32) were part of the CUACC

767 768 Bio-AD longitudinal observational study and were diagnosed based on an interdisciplinary consensus 769 conference with review of cognitive testing, neurological examination, clinical dementia rating scale (CDR), 770 and brain MRI (COMIRB# 15-1774; Dr Bettcher). Participants with mild-to-moderate AD were from our published Phase II, double-blind, randomized, placebo-controlled trial ³³ with recombinant human GM-CSF 771 772 (the "sargramostim/GM-CSF AD trial") (COMIRB # 12-1273; NCT 01409915). We include available 773 plasma samples taken at the baseline visit prior to treatment with sargramostim/GM-CSF or placebo (n=36), 774 as well as available plasma samples taken at the end of three weeks of treatment with either GM-CSF (n=18) or placebo (n=18). Some plasma samples were unavailable for measurements of NfL and GFAP 775 776 concentrations.

777

Measurement of plasma biomarker concentrations: Concentrations of UCH-L1, GFAP, and NfL in plasma samples were assessed in healthy control participants and in participants with MCI due to AD using published methods ^{17,33} and the Quanterix single molecule array, or SIMOA[®], SR-X Analyzer system and the Neuro-4-Plex B kits. Concentrations of UCH-L1, GFAP, and NfL in the samples from mild-to-moderate AD participants in the sargramostim/GM-CSF AD trial were determined in our previously published manuscript using the same methods ³³.

784

Rat AD model: Animal research was approved by the University of Colorado Institutional Animal Care and Use Committee (IACUC#00878). The TgF344-AD rat was developed as a model of AD by inserting transgenes that express the Swedish mutant human *APP* (*APPsw*) and mutant human presenilin 1 (*PSEN1 delta E9*) genes that cause familial AD ³⁹. As a result, and due to the fact that the rat MAPT (Tau) gene resembles the human version, the TgF344-AD rats overexpress human A β peptide and develop the full complement of human AD brain pathology: amyloid deposits, p-Tau-positive neurofibrillary tangles, and neuronal loss. Untreated age-matched wild-type (WT) F344 rats were used as controls. The 18- to 20-monthmedRxiv preprint doi: https://doi.org/10.1101/2024.07.14.24310223; this version posted July 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. old TgF344-AD male rats were injected subcutaneously with GM-CSF (83.3 mg/kg/day; 5 days/week; n=7)

792 793 or with saline (200 ml/day; 5 days/week; n=7) for 24 injections total over 32 days. On day 32, the rats were 794 anesthetized with sodium pentobarbital, perfused intracardially with PBS for 5-7 min, and the brains were 795 removed rapidly. The right hemisphere was immersed in freshly prepared 4% paraformaldehyde (PFA) in 796 PBS for 24 h at 4 °C. After fixing with PFA, 4 mm-thick paraffin-embedded hippocampal brain sections were 797 mounted on glass slides and processed for immunohistochemistry for the apoptosis marker Caspase-3 (Cell 798 signaling Technology; Cat# 9662) and stained with DAPI. A detailed protocol for immunohistochemistry and imaging is described in ³⁸. We visually counted the numbers of Caspase-3-positive cells in the CA1, CA3, 799 800 and dentate gyrus/Hilus regions of the hippocampus (blinded as to genotype and treatment).

801

802 **Neuronal death calculation**: UCH-L1 is primarily a neuronal protein that is released from damaged neurons 803 in the brain, enters the CSF, and is ultimately released into the blood. Therefore, for each research 804 participant, it is possible to calculate the number of neurons that have released UCH-L1 in a given time 805 period based on the steady state concentration of plasma UCH-L1 ('C' in pg/ml from the individual participant data of Figure 1), the half-life of UCH-L1 (estimated to be approximately 8.5 hours ^{66,67}). the 806 807 volume of plasma in a typical adult person (3,500 ml), and the amount of UCH-L1 per neuron (2.5% of total protein (250 pg) $^{25,26} = 6.25$ pg). Specifically, for each participant, the approximate number of neurons lost 808 809 per year can be calculated using the following formula:

810

811 Number of Neurons Lost Each Year = (C (pg/ml) x $\ln 2 x 3,500 \text{ ml}/(8.5 \text{ h x } 6.25 \text{ pg/neuron}) x 24 \text{ h x } 365 \text{ days}$ 812

813 Statistical Analysis

Data were analyzed using mixed model regression, with unstructured error covariance on repeated measures, for the effects of biomarkers, disease status, and treatment on the logarithmic transforms of the plasma biomarkers of UCH-L1, GFAP, and NfL. Although data from healthy control participants and participants

817 with MCI due to AD were cross-sectional, the framework of mixed model regression could still be adapted. 818 as regression with independent data is merely a simplified version of regression with correlated data. Healthy 819 control, MCI due to AD, mild-to-moderate AD at baseline, mild-to-moderate AD treated with placebo/saline, 820 and mild-to-moderate AD treated with sargramostim/GM-CSF were allowed different covariance matrices. 821 Because the biomarker data were measured using 2 or 3 replicates, all of the observations were used, instead 822 of averaging replicates and weighting. The age effects were modeled as log-linear, with separate age slopes 823 and intercepts for healthy control, MCI due to AD, and mild-to-moderate AD. The intercept for mild-to-824 moderate AD depended on the treatment x study time, but a common age slope was assumed for all mild-tomoderate AD participants, and independent of treatment effects. The log linearity assumption was checked 825 graphically, and by comparing to spline fits ⁶⁸. Interactions with sex were also considered. Linear 826 827 combinations of model parameters were estimated, along with 95% confidence intervals, back transformed, 828 and tested. Histograms of the Coefficient of Variation among replicates found some biomarker measures obtained with the SIMOA[®], SR-X Analyzer system, particularly UCH-L1, for example, in analyses of the 829 830 effects of TBI, can have Coefficients of Variance much higher than 20%, indicating that the variance is an 831 inherent feature of the measure and not due, for example, to unreliable outliers. For example, a histogram of 832 the UCH-L1 coefficient of variance of the healthy controls is shown below:



834 There are known limitations to using biomarkers with high CVs in analyses, with most studies utilizing less 835 than 20% cutoffs at the higher end. The primary concern is that if analysis of the same sample twice yields 836 markedly different values, there are understandable concerns for reliability of measurement (and clinical 837 applicability). Variability of such measures limits their utility for assessing individuals from a small number 838 of replicates, but the laws of large numbers still allow us to estimate the average with a medium to large 839 sample. For cross-sectional comparisons between large cohorts, the average or log average of individual 840 participant's replicate measures is often used because measures of UCH-L1 often show high variance ^{27,66,67,69}. UCH-L1 levels were FDA approved in 2018 as part of a measure of brain damage after TBI ⁷⁰. 841 842 Because some of our cohorts had two replicates for each participant (healthy controls and participants with 843 MCI due to AD from the Bio-AD) and some (healthy controls from the HTP, GM-CSF trial participants with 844 mild-to-moderate AD, and healthy controls from the MS study) had mostly three replicates for each 845 participant, and some of the biomarkers, especially UCH-L1, have high variability among replicates, we 846 decided in the modeling to use each replicate as a separate measure in the main analysis, rather than using the 847 averages of the individual participants' replicate measures. The variation among replicates was modeled by 848 introducing an additional noise term into the model. A common variance for the replicate noise term was 849 assumed across all treatments because of software option limitations. Model predicted values of the response, 850 along with pointwise standard errors, were plotted. All data calculations are provided in the **Supplementary** 851 Tables 2-4. As a test of confidence in the results, the averages of the participants' replicate measures for the 852 biomarkers were also modelled, weighted by the number of replicates, and the conclusions of age-associated 853 exponential increases in the three biomarkers, UCH-L1, NfL, and GFAP, and the effect of GM-CSF 854 treatment on reducing UCH-L1 levels were obtained. The overall results and conclusions were the same. 855 Univariate statistical significance was set at alpha = 0.05, two-sided, for all tests unless otherwise stated. 856 Statistics were computed using SAS 9.4 and R 4.1.3. There are remaining limitations to using this approach 857 in terms of both within-site and cross-site replication of findings, and we acknowledge that it is challenging

to move a biomarker into clinical practice for AD with high CVs, although it has been done for UCH-L1 in

859 TBI.

860

861 **References**

- Trollor, J.N., Smith, E., Agars, E., Kuan, S.A., Baune, B.T., Campbell, L., Samaras, K., Crawford, J.,
 Lux, O., Kochan, N.A., et al. (2012). The association between systemic inflammation and cognitive
 performance in the elderly: the Sydney Memory and Ageing Study. Age (Dordr) *34*, 1295-1308.
 10.1007/s11357-011-9301-x.
- Singh, P.P., Demmitt, B.A., Nath, R.D., and Brunet, A. (2019). The Genetics of Aging: A Vertebrate
 Perspective. Cell *177*, 200-220. 10.1016/j.cell.2019.02.038.
- Shcherbakov, D., Nigri, M., Akbergenov, R., Brilkova, M., Mantovani, M., Petit, P.I., Grimm, A.,
 Karol, A.A., Teo, Y., Sanchón, A.C., et al. (2022). Premature aging in mice with error-prone protein
 synthesis. Sci Adv 8, eabl9051. 10.1126/sciadv.abl9051.
- 4. Potter, H. (1991). Review and hypothesis: Alzheimer disease and Down syndrome--chromosome 21 nondisjunction may underlie both disorders. Am J Hum Genet 48, 1192-1200.
- Mattson, M.P., Longo, V.D., and Harvie, M. (2017). Impact of intermittent fasting on health and disease processes. Ageing Res Rev *39*, 46-58. 10.1016/j.arr.2016.10.005.
- Maegawa, S., Lu, Y., Tahara, T., Lee, J.T., Madzo, J., Liang, S., Jelinek, J., Colman, R.J., and Issa, J.J.
 (2017). Caloric restriction delays age-related methylation drift. Nat Commun 8, 539. 10.1038/s41467-017-00607-3.
- Lalli, M.A., Bettcher, B.M., Arcila, M.L., Garcia, G., Guzman, C., Madrigal, L., Ramirez, L., Acosta-Uribe, J., Baena, A., Wojta, K.J., et al. (2015). Whole-genome sequencing suggests a chemokine gene cluster that modifies age at onset in familial Alzheimer's disease. Molecular psychiatry 20, 1294-1300. 10.1038/mp.2015.131.
- 882 8. Frasca, D., and Blomberg, B.B. (2016). Inflammaging decreases adaptive and innate immune 883 responses in mice and humans. Biogerontology *17*, 7-19. 10.1007/s10522-015-9578-8.
- Bettcher, B.M., Watson, C.L., Walsh, C.M., Lobach, I.V., Neuhaus, J., Miller, J.W., Green, R., Patel,
 N., Dutt, S., Busovaca, E., et al. (2014). Interleukin-6, age, and corpus callosum integrity. PloS one 9,
 e106521. 10.1371/journal.pone.0106521 [doi].
- Boyle, P.A., Yu, L., Wilson, R.S., Leurgans, S.E., Schneider, J.A., and Bennett, D.A. (2018). Personspecific contribution of neuropathologies to cognitive loss in old age. Ann Neurol *83*, 74-83.
 10.1002/ana.25123.
- Risacher, S.L., Anderson, W.H., Charil, A., Castelluccio, P.F., Shcherbinin, S., Saykin, A.J., and
 Schwarz, A.J. (2017). Alzheimer disease brain atrophy subtypes are associated with cognition and
 rate of decline. Neurology *89*, 2176-2186. 10.1212/wnl.00000000004670.
- 12. Duara, R., Loewenstein, D.A., Potter, E., Appel, J., Greig, M.T., Urs, R., Shen, Q., Raj, A., Small, B.,
 Barker, W., et al. (2008). Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer
 disease. Neurology *71*, 1986-1992. 10.1212/01.wnl.0000336925.79704.9f.
- Hyman, B.T., Van Hoesen, G.W., Damasio, A.R., and Barnes, C.L. (1984). Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 225, 1168-1170.
 10.1126/science.6474172.
- Alves, F., Kalinowski, P., and Ayton, S. (2023). Accelerated Brain Volume Loss Caused by Anti-βAmyloid Drugs: A Systematic Review and Meta-analysis. Neurology *100*, e2114-e2124.
 10.1212/wnl.00000000207156.
- 902 15. Potter, H. (2001). Beyond beta protein—the essential role of inflammation in Alzheimer Amyloid
 903 formation (Prominent Press).

medRxiv preprint doi: https://doi.org/10.1101/2024.07.14.24310223; this version posted July 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
 Ahmed, M.M., Johnson, N.R., Boyd, T.D., Coughlan, C., Chial, H.J., and Potter, H. (2021). Innate

- Ahmed, M.M., Johnson, N.R., Boyd, T.D., Coughlan, C., Chial, H.J., and Potter, H. (2021). Innate
 Immune System Activation and Neuroinflammation in Down Syndrome and Neurodegeneration:
 Therapeutic Targets or Partners? Front Aging Neurosci 13, 718426. 10.3389/fnagi.2021.718426.
- Bettcher, B.M., Olson, K.E., Carlson, N.E., McConnell, B.V., Boyd, T., Adame, V., Solano, D.A.,
 Anton, P., Markham, N., Thaker, A.A., et al. (2021). Astrogliosis and episodic memory in late life:
 higher GFAP is related to worse memory and white matter microstructure in healthy aging and
 Alzheimer's disease. Neurobiol Aging *103*, 68-77. 10.1016/j.neurobiolaging.2021.02.012.
- 18. McGeer, P.L., Schulzer, M., and McGeer, E.G. (1996). Arthritis and anti-inflammatory agents as
 possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology
 47, 425-432. 10.1212/wnl.47.2.425.
- P14
 P15
 P15
 P16
 P17
 Zhou, M., Xu, R., Kaelber, D.C., and Gurney, M.E. (2020). Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer's disease in patients with rheumatoid arthritis and psoriasis. PLoS One *15*, e0229819. 10.1371/journal.pone.0229819.
- Oh, H.S., Rutledge, J., Nachun, D., Pálovics, R., Abiose, O., Moran-Losada, P., Channappa, D., Urey,
 D.Y., Kim, K., Sung, Y.J., et al. (2023). Organ aging signatures in the plasma proteome track health
 and disease. Nature 624, 164-172. 10.1038/s41586-023-06802-1.
- 21. Zecca, C., Pasculli, G., Tortelli, R., Dell'Abate, M.T., Capozzo, R., Barulli, M.R., Barone, R.,
 Accogli, M., Arima, S., Pollice, A., et al. (2021). The Role of Age on Beta-Amyloid(1-42) Plasma
 Levels in Healthy Subjects. Front Aging Neurosci 13, 698571. 10.3389/fnagi.2021.698571.
- Shir, D., Mielke, M.M., Hofrenning, E.I., Lesnick, T.G., Knopman, D.S., Petersen, R.C., Jack, C.R.,
 Algeciras-Schimnich, A., Vemuri, P., and Graff-Radford, J. (2023). Associations of
 Neurodegeneration Biomarkers in Cerebrospinal Fluid with Markers of Alzheimer's Disease and
 Vascular Pathology. J Alzheimers Dis 92, 887-898. 10.3233/jad-221015.
- Morgan, A.R., Touchard, S., Leckey, C., O'Hagan, C., Nevado-Holgado, A.J., Barkhof, F., Bertram,
 L., Blin, O., Bos, I., Dobricic, V., et al. (2019). Inflammatory biomarkers in Alzheimer's disease
 plasma. Alzheimers Dement 15, 776-787. 10.1016/j.jalz.2019.03.007.
- 930 24. Ohrfelt, A., Johansson, P., Wallin, A., Andreasson, U., Zetterberg, H., Blennow, K., and Svensson, J.
 931 (2016). Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in
 932 Patients with Alzheimer's Disease. Dement Geriatr Cogn Dis Extra 6, 283-294. 10.1159/000447239.
- Wang, K.K., Yang, Z., Sarkis, G., Torres, I., and Raghavan, V. (2017). Ubiquitin C-terminal
 hydrolase-L1 (UCH-L1) as a therapeutic and diagnostic target in neurodegeneration, neurotrauma and
 neuro-injuries. Expert Opin Ther Targets 21, 627-638. 10.1080/14728222.2017.1321635.
- Butterfield, D.A. (2021). Ubiquitin carboxyl-terminal hydrolase L-1 in brain: Focus on its oxidative/nitrosative modification and role in brains of subjects with Alzheimer disease and mild cognitive impairment. Free Radic Biol Med 177, 278-286. 10.1016/j.freeradbiomed.2021.10.036.
- Korley, F.K., Jain, S., Sun, X., Puccio, A.M., Yue, J.K., Gardner, R.C., Wang, K.K.W., Okonkwo,
 D.O., Yuh, E.L., Mukherjee, P., et al. (2022). Prognostic value of day-of-injury plasma GFAP and
 UCH-L1 concentrations for predicting functional recovery after traumatic brain injury in patients
 from the US TRACK-TBI cohort: an observational cohort study. Lancet Neurol *21*, 803-813.
 10.1016/s1474-4422(22)00256-3.
- Graff-Radford, J., Mielke, M.M., Hofrenning, E.I., Kouri, N., Lesnick, T.G., Moloney, C.M.,
 Rabinstein, A., Cabrera-Rodriguez, J.N., Rothberg, D.M., Przybelski, S.A., et al. (2022). Association
 of plasma biomarkers of amyloid and neurodegeneration with cerebrovascular disease and
 Alzheimer's disease. Neurobiol Aging *119*, 1-7. 10.1016/j.neurobiolaging.2022.07.006.
- 948 29. Brum, W.S., Ashton, N.J., Simrén, J., di Molfetta, G., Karikari, T.K., Benedet, A.L., Zimmer, E.R., 949 Lantero-Rodriguez, J., Montoliu-Gaya, L., Jeromin, A., et al. (2023). Biological variation estimates of disease 950 Alzheimer's plasma biomarkers in healthy individuals. Alzheimers Dement. 951 10.1002/alz.13518.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.14.24310223; this version posted July 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
 Liu, H., Povysheva, N., Rose, M.E., Mi, Z., Banton, J.S., Li, W., Chen, F., Reay, D.P., Barrionuevo,

- 30. Liu, H., Povysheva, N., Rose, M.E., Mi, Z., Banton, J.S., Li, W., Chen, F., Reay, D.P., Barrionuevo,
 G., Zhang, F., and Graham, S.H. (2019). Role of UCHL1 in axonal injury and functional recovery
 after cerebral ischemia. Proc Natl Acad Sci U S A *116*, 4643-4650. 10.1073/pnas.1821282116.
- Smith, D.L., Pozueta, J., Gong, B., Arancio, O., and Shelanski, M. (2009). Reversal of long-term
 dendritic spine alterations in Alzheimer disease models. Proc Natl Acad Sci U S A *106*, 16877-16882.
 10.1073/pnas.0908706106.
- Brum, W.S., Ashton, N.J., Simrén, J., di Molfetta, G., Karikari, T.K., Benedet, A.L., Zimmer, E.R.,
 Lantero-Rodriguez, J., Montoliu-Gaya, L., Jeromin, A., et al. (2024). Biological variation estimates of
 Alzheimer's disease plasma biomarkers in healthy individuals. Alzheimers Dement 20, 1284-1297.
 10.1002/alz.13518.
- 962 33. Potter, H., Woodcock, J.H., Boyd, T.D., Coughlan, C.M., O'Shaughnessy, J.R., Borges, M.T., Thaker,
 963 A.A., Raj, B.A., Adamszuk, K., Scott, D., et al. (2021). Safety and efficacy of sargramostim (GM964 CSF) in the treatment of Alzheimer's disease. Alzheimers Dement (N Y) 7, e12158.
 965 10.1002/trc2.12158.
- Kashon, M.L., Ross, G.W., O'Callaghan, J.P., Miller, D.B., Petrovitch, H., Burchfiel, C.M., Sharp,
 D.S., Markesbery, W.R., Davis, D.G., Hardman, J., et al. (2004). Associations of cortical astrogliosis
 with cognitive performance and dementia status. J Alzheimers Dis *6*, 595-604; discussion 673-581.
 10.3233/jad-2004-6604.
- Boyd, T.D., Bennett, S.P., Mori, T., Governatori, N., Runfeldt, M., Norden, M., Padmanabhan, J.,
 Neame, P., Wefes, I., Sanchez-Ramos, J., et al. (2010). GM-CSF upregulated in rheumatoid arthritis
 reverses cognitive impairment and amyloidosis in Alzheimer mice. J Alzheimers Dis 21, 507-518.
 10.3233/jad-2010-091471.
- Kiyota, T., Machhi, J., Lu, Y., Dyavarshetty, B., Nemati, M., Yokoyama, I., Mosley, R.L., and
 Gendelman, H.E. (2018). Granulocyte-macrophage colony-stimulating factor neuroprotective
 activities in Alzheimer's disease mice. J Neuroimmunol *319*, 80-92. 10.1016/j.jneuroim.2018.03.009.
- 37. Castellano, J.M., Mosher, K.I., Abbey, R.J., McBride, A.A., James, M.L., Berdnik, D., Shen, J.C.,
 37. Zou, B., Xie, X.S., Tingle, M., et al. (2017). Human umbilical cord plasma proteins revitalize
 bippocampal function in aged mice. Nature 544, 488-492. 10.1038/nature22067.
- Ahmed, M.M., Wang, A.C., Elos, M., Chial, H.J., Sillau, S., Solano, D.A., Coughlan, C., Aghili, L.,
 Anton, P., Markham, N., et al. (2022). The innate immune system stimulating cytokine GM-CSF
 improves learning/memory and interneuron and astrocyte brain pathology in Dp16 Down syndrome
 mice and improves learning/memory in wild-type mice. Neurobiol Dis *168*, 105694.
 10.1016/j.nbd.2022.105694.
- Solution 239. Cohen, R.M., Rezai-Zadeh, K., Weitz, T.M., Rentsendorj, A., Gate, D., Spivak, I., Bholat, Y.,
 Vasilevko, V., Glabe, C.G., Breunig, J.J., et al. (2013). A transgenic Alzheimer rat with plaques, tau
 pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss. J Neurosci *33*, 6245-6256.
 10.1523/jneurosci.3672-12.2013.
- 40. Rohn, T.T., and Head, E. (2008). Caspase activation in Alzheimer's disease: early to rise and late to bed. Rev Neurosci *19*, 383-393. 10.1515/revneuro.2008.19.6.383.
- Means, J.C., Gerdes, B.C., Kaja, S., Sumien, N., Payne, A.J., Stark, D.A., Borden, P.K., Price, J.L.,
 and Koulen, P. (2016). Caspase-3-Dependent Proteolytic Cleavage of Tau Causes Neurofibrillary
 Tangles and Results in Cognitive Impairment During Normal Aging. Neurochem Res *41*, 2278-2288.
 10.1007/s11064-016-1942-9.
- 42. Zhang, P., Kishimoto, Y., Grammatikakis, I., Gottimukkala, K., Cutler, R.G., Zhang, S.,
 Abdelmohsen, K., Bohr, V.A., Misra Sen, J., Gorospe, M., and Mattson, M.P. (2019). Senolytic
 therapy alleviates Aβ-associated oligodendrocyte progenitor cell senescence and cognitive deficits in
 an Alzheimer's disease model. Nat Neurosci 22, 719-728. 10.1038/s41593-019-0372-9.
- Potter, H., and Wisniewski, T. (2012). Apolipoprotein e: essential catalyst of the Alzheimer amyloid cascade. Int J Alzheimers Dis 2012, 489428. 10.1155/2012/489428.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.14.24310223; this version posted July 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
 Rogers, J.T., Leiter, L.M., McPhee, J., Cahill, C.M., Zhan, S.S., Potter, H., and Nilsson, L.N. (1999).

- 44. Rogers, J.T., Leiter, L.M., McPhee, J., Cahill, C.M., Zhan, S.S., Potter, H., and Nilsson, L.N. (1999).
 Translation of the alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1
 through 5'-untranslated region sequences. J Biol Chem 274, 6421-6431. 10.1074/jbc.274.10.6421.
- 45. Gage, F.H. (2019). Adult neurogenesis in mammals. Science *364*, 827-828. 10.1126/science.aav6885.
- Alves, F., Kallinowski, P., and Ayton, S. (2023). Accelerated Brain Volume Loss Caused by Anti-β Amyloid Drugs: A Systematic Review and Meta-analysis. Neurology.
 10.1212/wnl.00000000207156.
- 47. Salloway, S., Chalkias, S., Barkhof, F., Burkett, P., Barakos, J., Purcell, D., Suhy, J., Forrestal, F.,
 Tian, Y., Umans, K., et al. (2022). Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies
 Evaluating Aducanumab in Patients With Early Alzheimer Disease. JAMA Neurol 79, 13-21.
 10.1001/jamaneurol.2021.4161.
- 48. Kim, N.K., Choi, B.H., Huang, X., Snyder, B.J., Bukhari, S., Kong, T.H., Park, H., Park, H.C., Park,
 S.R., and Ha, Y. (2009). Granulocyte-macrophage colony-stimulating factor promotes survival of
 dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced murine
 Parkinson's disease model. Eur J Neurosci 29, 891-900. 10.1111/j.1460-9568.2009.06653.x.
- 49. Kelso, M.L., Elliott, B.R., Haverland, N.A., Mosley, R.L., and Gendelman, H.E. (2015). Granulocytemacrophage colony stimulating factor exerts protective and immunomodulatory effects in cortical
 trauma. J Neuroimmunol 278, 162-173. 10.1016/j.jneuroim.2014.11.002.
- 50. Kong, T., Choi, J.K., Park, H., Choi, B.H., Snyder, B.J., Bukhari, S., Kim, N.K., Huang, X., Park,
 S.R., Park, H.C., and Ha, Y. (2009). Reduction in programmed cell death and improvement in
 functional outcome of transient focal cerebral ischemia after administration of granulocytemacrophage colony-stimulating factor in rats. Laboratory investigation. J Neurosurg *111*, 155-163.
 10.3171/2008.12.JNS08172.
- Schneider, U.C., Schilling, L., Schroeck, H., Nebe, C.T., Vajkoczy, P., and Woitzik, J. (2007). 024 51. 025 Granulocyte-macrophage colony-stimulating factor-induced vessel growth restores cerebral blood 026 after bilateral carotid artery occlusion. Stroke 38. 1320-1328. supply 027 10.1161/01.STR.0000259707.43496.71.
- 52. Jim, H.S., Boyd, T.D., Booth-Jones, M., Pidala, J., and Potter, H. (2012). Granulocyte Macrophage
 Colony Stimulating Factor Treatment is Associated with Improved Cognition in Cancer Patients.
 Brain Disord Ther 1. 10.4172/bdt.1000101.
- Olson, K.E., Abdelmoaty, M.M., Namminga, K.L., Lu, Y., Obaro, H., Santamaria, P., Mosley, R.L.,
 and Gendelman, H.E. (2023). An open-label multiyear study of sargramostim-treated Parkinson's
 disease patients examining drug safety, tolerability, and immune biomarkers from limited case
 numbers. Transl Neurodegener *12*, 26. 10.1186/s40035-023-00361-1.
- 54. Krieger, M., Both, M., Kranig, S.A., Pitzer, C., Klugmann, M., Vogt, G., Draguhn, A., and Schneider,
 A. (2012). The hematopoietic cytokine granulocyte-macrophage colony stimulating factor is
 important for cognitive functions. Sci Rep 2, 697. 10.1038/srep00697.
- 55. Buschmann, I.R., Busch, H.J., Mies, G., and Hossmann, K.A. (2003). Therapeutic induction of
 arteriogenesis in hypoperfused rat brain via granulocyte-macrophage colony-stimulating factor.
 Circulation *108*, 610-615. 10.1161/01.CIR.0000074209.17561.99.
- Choi, J.K., Kim, K.H., Park, H., Park, S.R., and Choi, B.H. (2011). Granulocyte macrophage-colony stimulating factor shows anti-apoptotic activity in neural progenitor cells via JAK/STAT5-Bcl-2 pathway. Apoptosis *16*, 127-134. 10.1007/s10495-010-0552-2.
- Huang, X., Choi, J.K., Park, S.R., Ha, Y., Park, H., Yoon, S.H., Park, H.C., Park, J.O., and Choi, B.H.
 (2007). GM-CSF inhibits apoptosis of neural cells via regulating the expression of apoptosis-related proteins. Neurosci Res 58, 50-57. 10.1016/j.neures.2007.01.015.
- 58. Krüger, C., Laage, R., Pitzer, C., Schäbitz, W.R., and Schneider, A. (2007). The hematopoietic factor
 GM-CSF (granulocyte-macrophage colony-stimulating factor) promotes neuronal differentiation of
 adult neural stem cells in vitro. BMC Neurosci 8, 88. 10.1186/1471-2202-8-88.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.14.24310223; this version posted July 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
 Wu, Y.C., Wen, Q., Thukral, R., Yang, H.C., Gill, J.M., Gao, S., Lane, K.A., Meier, T.B., Riggen,

- Wu, Y.C., Wen, Q., Thukral, R., Yang, H.C., Gill, J.M., Gao, S., Lane, K.A., Meier, T.B., Riggen,
 L.D., Harezlak, J., et al. (2023). Longitudinal Associations Between Blood Biomarkers and White
 Matter MRI in Sport-Related Concussion: A Study of the NCAA-DoD CARE Consortium. Neurology
 101, e189-e201. 10.1212/wnl.00000000207389.
- 60. Potter, H., Chial, H.J., Caneus, J., Elos, M., Elder, N., Borysov, S., and Granic, A. (2019).
 Chromosome Instability and Mosaic Aneuploidy in Neurodegenerative and Neurodevelopmental
 Disorders. Front Genet 10, 1092. 10.3389/fgene.2019.01092.
- 61. Gorgoulis, V., Adams, P.D., Alimonti, A., Bennett, D.C., Bischof, O., Bishop, C., Campisi, J.,
 Collado, M., Evangelou, K., Ferbeyre, G., et al. (2019). Cellular Senescence: Defining a Path
 Forward. Cell *179*, 813-827. 10.1016/j.cell.2019.10.005.
- 62. Herdy, J.R., Traxler, L., Agarwal, R.K., Karbacher, L., Schlachetzki, J.C.M., Boehnke, L., Zangwill,
 D., Galasko, D., Glass, C.K., Mertens, J., and Gage, F.H. (2022). Increased post-mitotic senescence in
 aged human neurons is a pathological feature of Alzheimer's disease. Cell Stem Cell 29, 16371652.e1636. 10.1016/j.stem.2022.11.010.
- 63. Chaib, S., Tchkonia, T., and Kirkland, J.L. (2022). Cellular senescence and senolytics: the path to the clinic. Nat Med 28, 1556-1568. 10.1038/s41591-022-01923-y.
- Araya, P., Kinning, K.T., Coughlan, C., Smith, K.P., Granrath, R.E., Enriquez-Estrada, B.A., Worek,
 K., Sullivan, K.D., Rachubinski, A.L., Wolter-Warmerdam, K., et al. (2022). IGF1 deficiency
 integrates stunted growth and neurodegeneration in Down syndrome. Cell Rep *41*, 111883.
 10.1016/j.celrep.2022.111883.
- 65. Zhang, M., Chen, M.Y., Wang, S.L., Ding, X.M., Yang, R., Li, J., and Jiang, G.H. (2022). Association
 of Ubiquitin C-Terminal Hydrolase-L1 (Uch-L1) serum levels with cognition and brain energy
 metabolism. Eur Rev Med Pharmacol Sci 26, 3656-3663. 10.26355/eurrev_202205_28861.
- Papa, L., Brophy, G.M., Welch, R.D., Lewis, L.M., Braga, C.F., Tan, C.N., Ameli, N.J., Lopez, M.A.,
 Haeussler, C.A., Mendez Giordano, D.I., et al. (2016). Time Course and Diagnostic Accuracy of Glial
 and Neuronal Blood Biomarkers GFAP and UCH-L1 in a Large Cohort of Trauma Patients With and
 Without Mild Traumatic Brain Injury. JAMA Neurol *73*, 551-560. 10.1001/jamaneurol.2016.0039.
- 67. Hicks, C., Dhiman, A., Barrymore, C., and Goswami, T. (2022). Traumatic Brain Injury Biomarkers,
 67. Simulations and Kinetics. Bioengineering (Basel) *9*. 10.3390/bioengineering9110612.
- Wang, Y. (2011). Smoothing Splines: Methods and Applications (CRC Press: Taylor & Francis
 Group. A Chapman & Hall Book).
- 69. Czeiter, E., Amrein, K., Gravesteijn, B.Y., Lecky, F., Menon, D.K., Mondello, S., Newcombe, V.F.J.,
 Richter, S., Steyerberg, E.W., Vyvere, T.V., et al. (2020). Blood biomarkers on admission in acute
 traumatic brain injury: Relations to severity, CT findings and care path in the CENTER-TBI study.
 EBioMedicine 56, 102785. 10.1016/j.ebiom.2020.102785.
- 70. Bazarian, J.J., Biberthaler, P., Welch, R.D., Lewis, L.M., Barzo, P., Bogner-Flatz, V., Gunnar
 Brolinson, P., Büki, A., Chen, J.Y., Christenson, R.H., et al. (2018). Serum GFAP and UCH-L1 for
 prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational
 study. Lancet Neurol *17*, 782-789. 10.1016/s1474-4422(18)30231-x.
- 089
- 090
- 091 092